Research programme: gene therapy - RetroSense Therapeutics/University of California San DiegoAlternative Names: Red activatable channelrhodopsin
Latest Information Update: 12 Sep 2016
At a glance
- Originator University of California, San Diego
- Developer RetroSense Therapeutics
- Class Gene therapies
- Mechanism of Action Gene stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Eye disorders